The expression of histone lysine demethylase 2B in canine hemangiosarcoma is associated with disease progression.
KDM2B
canine hemangiosarcoma
disease progression
epigenetics
metastasis
patient profile
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
02
12
2021
received:
06
09
2021
accepted:
16
12
2021
pubmed:
21
12
2021
medline:
18
5
2022
entrez:
20
12
2021
Statut:
ppublish
Résumé
Canine hemangiosarcoma (HSA), a highly fatal mesenchymal tumour of dogs, originates from the endothelial cells lining of blood vessels. It is characterized by a short survival time with a mean survival time of only 4 months. Recently, we showed that histone lysine demethylase 2B (KDM2B) was highly expressed in canine HSA and was important in HSA tumour cell survival by positively regulating DNA repair mechanisms. KDM2B has been reported to be related to disease progression and patient survival in several human cancers. Thus, in this study, we studied the relationship of KDM2B expression levels with several patient clinical profiles to investigate the role of KDM2B in clinical HSA tumours. We analysed 37 canine HSA cases and found that KDM2B is highly expressed in stage 3 HSA compared to stage 1 HSA. High KDM2B expression was also found in male dogs compared to female dogs. No correlation was observed between KDM2B expression and age. Classifying HSA patients into high and low KDM2B expression groups revealed that the high KDM2B group showed shorter overall survival than the low KDM2B group. Based on these results, we suggest that KDM2B expression is associated with disease progression in HSA.
Substances chimiques
Histones
0
Histone Demethylases
EC 1.14.11.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
529-534Subventions
Organisme : Japan Society for the Promotion of Science
ID : 20K15654
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Brown NO, Patnaik AK, MacEwen EG. Canine hemangiosarcoma: retrospective analysis of 104 cases. J Am Vet Med Assoc. 1985;186:56-58.
Wendelburg KM, Price LL, Burgess KE, Lyons JA, Lew FH, Berg J. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012). J Am Vet Med Assoc. 2015;247:393-403.
Prymak CL, McKee M, Goldschmidt LG. Epidemiologic, clinical, pathologic, and prognostic characteristics of splenic hemangiosarcoma and splenic hematoma in dogs: 217 cases (1985). J Am Vet Med Assoc. 1988;193:706-712.
Johnson KA, Powers BE, Withrow SJ, Sheetz MJ, Curtis CR, Wrigley RH. Splenomegaly in dogs: predictors of neoplasia and survival after splenectomy. J Vet Intern Med. 1989;3:160-166.
Boston SE, Higginson G, Monteith G. Concurrent splenic and right atrial mass at presentation in dogs with HSA: a retrospective study. J Am Anim Hosp Assoc. 2011;47:336-341.
Spangler W, Ulbertson M. Prevalence and type of splenic diseases in cats: 455 cases (1985-1991). J Am Vet Med Assoc. 1992;201:773-776.
Schultheiss PC. A retrospective study of visceral and nonvisceral hemangiosarcoma and hemangiomas in domestic animals. J Vet Diagn Invest. 2004;16:522-526.
Gulay KCM, Aoshima K, Shibata Y, et al. KDM2B promotes cell viability by enhancing DNA damage response in canine hemangiosarcoma. J Genet Genom. 2021;48:618-630.
He J, Nguyen AT, Zhang Y. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood. 2011;117(14):3869-3880.
Kottakis F, Foltopoulou P, Sanidas I, et al. NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells. Cancer Res. 2014;74(14):3935-46.
Frescas D, Guardavaccaro D, Bassermann F, Koyama-Nasu R, Pagano M. JHDM1B/FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes. Nature. 2007;450:309-313.
Kuang Y, Lu F, Guo J, et al. Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo. Onco Targets Ther. 2017;10:3131.
Tzatsos A, Paskaleva P, Ferrari F, et al. KDM2B promotes pancreatic cancer via polycomb-dependent and -independent transcriptional programs. J Clin Invest. 2013;123:727.
Hong X, Xu Y, Qiu X, et al. MiR-448 promotes glycolytic metabolism of gastric cancer by downregulating KDM2B. Oncotarget. 2016;7:22092-22102.
Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC, Tsichlis PN. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell. 2011;43(2):285-98.
Ge R, Wang Z, Zeng Q, Xu X, Olumi AF. F-box protein 10, an NF-κB-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway. Cell Death Differ. 2011;18:1184-1195.
Kurt IC, Sur I, Kaya E, et al. KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL. Cell Death Dis. 2017;8(6):e2897.
Wang Y, Zang J, Zhang D, Sun Z, Qiu B, Wang X. KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth. Onco Targets Ther. 2018;11:201.
Zheng Q, Fan H, Meng Z, et al. Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription. Acta Biochim Biophys Sin. 2018;50:897-904.
Quan M, Chen Z, Jiao F, et al. Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression. J Exp Clin Cancer Res. 2020;39(1):13.
Kuang Y, Xu H, Lu F, et al. Inhibition of microRNA let-7b expression by KDM2B promotes cancer progression by targeting EZH2 in ovarian cancer. Cancer Sci. 2021;112:231.
Bankhead P, Loughrey MB, Fernández JA, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.
Batschinski K, Nobre A, Vargas-Mendez E, et al. Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014). Can Vet J. 2018;59:967-972.
Camp RL, Dolled-Filhart M, Rimm DL. X-Tile. Clin Cancer Res. 2004;10:7252-7259.
Karoopongse E, Yeung C, Byon J, et al. The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy. PLoS One. 2014;9:817.
Andricovich J, Kai Y, Peng W, Foudi A, Tzatsos A. Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis. J Clin Invest. 2016;126:905.
Vali VE, Bienzle D, Meuten DJ, Linder KE. Tumors of the hemolymphatic system. In: Meuten DJ, ed. Tumors in Domestic Animals. 5th ed. John Wiley & Sons, Ltd; 2016:309-313.
Robinson KL, Bryan ME, Atkinson ES, Keeler MR, Hahn AW, Bryan JN. Neutering is associated with developing hemangiosarcoma in dogs in the veterinary medical database: an age and time-period matched case-control study (1964-2003). Can Vet J. 2020;61:499-504.